Compare British American Tobacco PLC (BTI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Recursion Pharmaceuticals Inc — how do they compare? British American Tobacco PLC trades at $56.74 (market cap $122.36B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.81B). The key difference: British American Tobacco PLC is far larger — about 67.6× Recursion Pharmaceuticals Inc's market cap, and British American Tobacco PLC pays a 5.88% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BTI | RXRX | |
|---|---|---|
Market Cap | $122.36B | $1.81B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $6.79 |
52-Week Low | $50.39 | $2.84 |
Enterprise Value | $166.31B | $1.33B |
Dividend Yield | 5.88% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
